Hydroxyflutamide intraprostatic - LIDDS

Drug Profile

Hydroxyflutamide intraprostatic - LIDDS

Alternative Names: 2-hydroxyflutamide - LIDDS; Liproca Depot; Liproca® Depot - LIDDS; NZ 2 HOF; OH-flutamide

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LIDDS
  • Developer LIDDS; Uppsala University
  • Class Anilides; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 09 Jul 2018 LIDDS transfers licensing rights for Hydroxyflutamide intraprostatic from Jiangsu Ambition Medical to Jiangxi Puheng Pharmaceuticals in China
  • 05 Jun 2018 LIDDS has patent protection for devices and methods for the reconstitution and administration of hydroxyflutamide intraprostatic and other NanoZolid® formulations in Europe
  • 16 May 2018 Hydroxyflutamide intraprostatic licensed to Jiangsu Ambition Medical in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top